Compare First Horizon Corporation Common Stock (FHN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Horizon Corporation Common Stock vs Mesoblast Limited — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.79B), while Mesoblast Limited trades at $13.76 (market cap $1.83B). The key difference: First Horizon Corporation Common Stock is far larger — about 5.9× Mesoblast Limited's market cap, and First Horizon Corporation Common Stock pays a 2.99% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Mesoblast Limited for 15 Days on average.
| FHN | MESO | |
|---|---|---|
Market Cap | $10.79B | $1.83B |
Volume | 8,579,466 | 259,445 |
Sector | Financials | Health |
52-Week High | $26.23 | $20.96 |
52-Week Low | $19.94 | $13.19 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $14.10B | $1.91B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Horizon Corporation Common Stock
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
